Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
New mutations in cat genome identified as causes of human eye diseases

New mutations in cat genome identified as causes of human eye diseases

Major scientific breakthrough in understanding retinal degenerative diseases that cause blindness

Major scientific breakthrough in understanding retinal degenerative diseases that cause blindness

Bionic Vision Australia reports positive results of prototype implant in patients with RP-induced vision loss

Bionic Vision Australia reports positive results of prototype implant in patients with RP-induced vision loss

Envision Conference 2014 kicks off with presentation of two prestigious awards

Envision Conference 2014 kicks off with presentation of two prestigious awards

French Ministry of Health approves financial support for Second Sight Argus II Retinal Prosthesis System

French Ministry of Health approves financial support for Second Sight Argus II Retinal Prosthesis System

Retina's Alpha IMS microchip receives NUB innovation status from Germany statutory health insurance

Retina's Alpha IMS microchip receives NUB innovation status from Germany statutory health insurance

Iodine supplement can reduce central foveal swelling in RP patients with CME

Iodine supplement can reduce central foveal swelling in RP patients with CME

New chemical compound protects against blindness and diabetes in animals

New chemical compound protects against blindness and diabetes in animals

New approach for developing personalized gene therapies to treat retinitis pigmentosa

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Light-sensitive molecule enables noninvasive silencing of neurons

Light-sensitive molecule enables noninvasive silencing of neurons

University of Utah researcher to receive Nelson Trust Award for Retinitis Pigmentosa

University of Utah researcher to receive Nelson Trust Award for Retinitis Pigmentosa

Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals plans to merge with QLT

Researchers create three-dimensional complement of human retinal tissue in a dish

Researchers create three-dimensional complement of human retinal tissue in a dish

Researchers take step toward restoring natural, high-fidelity vision to blind people

Researchers take step toward restoring natural, high-fidelity vision to blind people

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

Scientists develop non-invasive technique to determine gene carriers  for retinitis pigmentosa

Scientists develop non-invasive technique to determine gene carriers for retinitis pigmentosa

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Second Sight's Argus II Retinal Prosthesis System selected for Forfait Innovation reimbursement

Second Sight's Argus II Retinal Prosthesis System selected for Forfait Innovation reimbursement